[go: up one dir, main page]

WO1992003175A1 - Dispositif d'inhalation - Google Patents

Dispositif d'inhalation Download PDF

Info

Publication number
WO1992003175A1
WO1992003175A1 PCT/GB1991/001357 GB9101357W WO9203175A1 WO 1992003175 A1 WO1992003175 A1 WO 1992003175A1 GB 9101357 W GB9101357 W GB 9101357W WO 9203175 A1 WO9203175 A1 WO 9203175A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
drawer
inhalation
body portion
chamber
Prior art date
Application number
PCT/GB1991/001357
Other languages
English (en)
Inventor
Stephen John Minshull
John Leck Hart
Steven Kent
Michael Trevor Shepherd
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017654A external-priority patent/GB9017654D0/en
Priority claimed from GB909024149A external-priority patent/GB9024149D0/en
Application filed by Fisons Plc filed Critical Fisons Plc
Publication of WO1992003175A1 publication Critical patent/WO1992003175A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • This invention relates to an improved medicament inhalation device, more particularly to such a device for use with medicament capsules.
  • European Patent Application No 406893 discloses a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber.
  • the piercing means are slidably mounted on the drawer, and must be actuated in an additional action following introduction of a capsule to the emptying chamber. This may be difficult for those with impaired hand movement, for example the elderly.
  • capsules are dispensed into the drawer from a capsule magazine with their longitudinal axis in an upright position. It has been found that more than one capsule may be dispensed into the drawer at a time, creating the risk of overdosing if both capsules are pierced, or jamming of the drawer.
  • a further disadvantage of this device is a tendency for capsules dispensed into the drawer to fall into the emptying chamber horizontally, which also results in jamming of the drawer.
  • capsules sometimes move vertically once in the chamber, leading to ineffective piercing by the piercing means.
  • a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the drawer comprises a body portion upon which the piercing means are mounted, and a pushing portion which is slidably mounted on the body portion and which bears against the capsule during movement of the drawer from the loading position to the inhalation position, the arrangement being such that relative movement of the body portion and the pushing portion in the inhalation position of the drawer results in the drawer adopting a piercing configuration in which the capsule is pierced by the capsule piercing means.
  • the device of the invention has the advantage that transport and piercing of a capsule may be achieved in one action which firstly moves the drawer from the loading position to the inhalation position and then causes adoption of the piercing configuration by relative movement of t.ne body portion and the pushing portion.
  • the device will be more readily operated by those with impaired hand movement, and will be more convenient for others, than prior art devices which require more than one action to achieve transport and piercing of a capsule.
  • the pushing portion may be biassed away from the body portion of the drawer by biassing means, for example a compression spring.
  • the biassing means may act to automatically reverse the relative movement of the body portion and the pushing portion which results in adoption of the piercing configuration, so that inhalation may take place through the device.
  • the pushing portion is restrained by a stop when the drawer is in the inhalation position.
  • the stop (or stops) may be provided adjacent to the emptying chamber. In this case, appropriate movement of the body portion of the drawer results in adoption of the piercing configuration of the drawer.
  • the piercing means are covered by the pushing portion except when the drawer is in (or approaching) the piercing configuration.
  • This may be achieved by providing through-going apertures or channels in the pushing portion which receive the piercing means when the drawer is not in the piercing position, and which allow the piercing means to pass through during relative movement of the body portion and the pushing portion.
  • the piercing means may comprise two rods each having a sharpened end.
  • the ends of the rods may be sharpened to a point or a blade.
  • the rods may be formed in one piece, for example they may be parts of a U-shaped double ended pin.
  • the capsule emptying chamber has a capsule entrance whose width is less than the diameter of the capsule. This restricts the movement of a capsule between arrival in the drawer and introduction to the chamber. For example, such a feature may prevent capsules falling into a horizontal position when they are intended to be transported and pierced in a vertical position.
  • biassing means are also provided, their stiffness is preferably sufficiently great that the resistance offered by a capsule as it is urged through the capsule entrance by the pushing portion does not result in a substantial perturbation of the biassing means: for example where the biassing means is a compression spring, the spring is not substantially compressed.
  • devices of the invention comprise a capsule magazine from which capsules are dispensed into the body portion of the drawer, for example by falling under gravity.
  • Controlled, individual dispensing of capsules is facilitated by provision of a shutter member on the body portion of the drawer, which closes off the drawer from the magazine when the drawer is not in the loading position. This prevents further capsules entering the drawer, which could result in jamming of the drawer or an overdose being administered to a patient.
  • the shutter member prevents ingress of moisture to the capsules remaining in the magazine.
  • the shutter member is preferably arranged so that it may further act to restrain movement of the capsule in the emptying chamber during piercing of the capsule.
  • Conventional means for dispersing powder in an entrained airstream may be provided in the air outlet, for example grids through which the airstream passes.
  • a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the air outlet is provided with one or more air inlets.
  • the air outlet to be provided with a pair of diametrically opposed air inlets adjacent to the capsule emptying chamber, and two pairs of diametrically opposed air inlets at the end of the air outlet remote from the capsule emptying chamber.
  • devices according to this aspect of the invention are able to deliver medicament to a patient with a much greater proportion of the particles having a size in the respirable range.
  • respirable range we mean sizes sufficiently small to penetrate deep into the lungs during inhalation, ie those having a mass median diameter in the range l-10 ⁇ m.
  • such devices require less inhalatory effort by a patient to inhale through them.
  • Figure 1 is an exploded perspective view, partly cut away, of a medicament inhalation device according to the invention which comprises a base portion and a capsule magazine;
  • Figure 2 is a cross sectional view in the plane II-II-II of
  • Figure 1 of the base portion of the device with a drawer in a loading position
  • Figure 3 is a cross sectional view along the line III-III of Figure 2;
  • Figure 4 is a view similar to that of Figure 2, but with the drawer in an inhalation position;
  • Figure 5 is a cross sectional view along the line V-V of
  • Figure 6 is a view similar to that of Figure 2, but with the drawer in a capsule piercing configuration; and Figure 7 is a cross sectional view along the line VII-VII of Figure 6.
  • a medicament inhalation device comprises a generally cylindrical base portion 2, upon which is coaxially and rotatably mounted a cylindrical capsule magazine 4.
  • Base portion 2 defines an inner space 6 which is more readily seen in Figures 2-7.
  • a cuboid member 8 depends from the upper wall 10 of base portion 2 into space 6.
  • Member 8 defines an upright cylindrical capsule emptying chamber 12 towards its rear end which communicates with an opening 14 in the front of base portion 2 via an upright rectangular passageway 16 whose width is slightly less than the diameter of a capsule C.
  • Two tangential air inlets 18 are provided at the base of chamber 12 which communicate with space 6. Space 6 in turn communicates with the atmosphere via air inlets 20 which take the form of niches in the side wall of opening 14.
  • Passageway 16 is also provided with an upright cylindrical capsule receiving chamber 22 towards its front end.
  • Capsule emptying chamber 12 is provided with an air outlet 24 which extends into a cylindrical shaft 26 which projects vertically from upper wall 10 of base portion 2.
  • a cross piece 28 delimits chamber 12 from air outlet 24, and serves to prevent capsule C escaping from chamber 12 through air outlet 24, as well as producing air turbulence which disperses entrained medicament, during inhalation.
  • Two diametrically opposed air inlets 30 empty into air outlet 24 just above cross piece 28. Air inlets 30 communicate with space 6 via passageways 32 which commence as vertical channels on the rear surface of member 8 and run through wall 10 and the wall of shaft 26. The air admitted by air inlets 30 serves to disperse entrained medicament during inhalation, and also to reduce the inhalatory effort required to inhale through the device.
  • a grid (not shown) is provided across air outlet 24 towards the top of shaft 26, which also serves to disperse entrained medicament during inhalation.
  • Magazine 4 is mounted on shaft 26, and is provided with ten circumferentially arranged vertical bores 34 which are each adapted to receive three medicament capsules. Magazine 4 abuts a gasket 42 attached to wall 10 so as to make an air tight seal. The bottom opening of each bore 34 may be brought into communication successively with aligned openings 38 and 40 in gasket 36 and wall 10 respectively by rotation about shaft 26.
  • An annular gasket 42 seals the upper ends of bores 34, and an annular plate 44 provided with four downwardly facing channels 46 is retained on gasket 36 by mouthpiece 48 which makes a snap fitting connection with magazine 4.
  • Channels 46 define two pairs of diametrically opposed air inlets which empty into the upper portion of air outlet 24 and communicate with the atmosphere via openings 50 in the mouthpiece.
  • the air admitted by channels 46 acts similarly to that admitted by air inlets 30 mentioned above.
  • a drawer 52 is slidably mounted on member 8 and comprises a body portion 54 and a pushing portion 56 which is slidably mounted on body portion 54.
  • a horizontally disposed compression spring 70 connects body portion 54 to pushing portion 56.
  • Body portion 54 has a generally U-shaped cross section, with a shutter 58 extending horizontally from the top of its front end, and a U-shaped double ended pin 60 mounted therein.
  • Shutter 58 is received by a space between the front portion of member 8 and wall 10
  • the base of body portion 54 is received by a space between member 8 and the base of base portion 2.
  • Pushing portion 56 is generally cuboid, with a concave back surface 62, and a pair of lateral wings 64 on each side surface which are received by channels 66 on the inner surface of the side walls of body portion 54. Lateral wings 64 pass through lateral slots 65 formed in the side walls of member 8 when drawer 52 is in the inhalation position.
  • the two ends of pin 60 are slidably received by two bores 68 which run through pushing portion 56.
  • Each side wall of body portion 54 has a through going bore 72 through which space 6 communicates with air inlets 18 when the drawer is in the inhalation position.
  • the device is operated as follows. With drawer 52 in the loading position shown in Figures 2 and 3, capsule C may fall under gravity from its bore 34 in magazine 4 into capsule receiving chamber 22 through opening 38 in gasket 36 and opening 40 in wall 10. Drawer 52 is then pushed radially inward by applying pressure to the front end of body portion 54. As this movement takes place, shutter 58 passes under opening 40 and prevents a second capsule from entering drawer 52. Also, force is transmitted via spring 70 to pushing portion 56 which bears against capsule C with its concave rear surface 62. Capsule C is consequently urged through passageway 16, and because the width of the passageway is less than the diameter of capsule C, the capsule remains in an upright position which is desirable for optimum piercing and avoidance of jamming of the drawer. The stiffness of spring 70 is such that the force necessary to urge capsule C through passageway 16 does not compress it substantially.
  • capsule C is delivered to capsule emptying chamber 12, and surface 62 of pushing portion 56 makes up part of the vertical wall of chamber 12. Also, lateral wings 64 of pushing portion 56 abut the end of slots 65 in member 8. Further inward movement of body portion 54 results in relative movement of body portion 54 and pushing portion 56 since pushing portion 56 is unable to move further inward because of its abutment with the end of slot 65. Compression of spring 70 accompanies this relative movement.
  • the two ends of pin 60 move through bores 68 and penetrate into capsule emptying chamber 12, and shutter 58 passes over the top of chamber 12 which restricts the vertical movement of capsule C.
  • Pin 60 first moves capsule C into a vertical position and then penetrates the capsule in the piercing configuration of the drawer which is shown in Figures 6 and 7, producing two openings.
  • the pressure on bo:ly portion 54 is then released and spring 70 urges body portion 54 radially outward so that the device attains once again the inhalation position shown in Figures 4 and 5.
  • a patient then places his lips over mouthpiece 48 and inhales. Air is drawn through air inlets 20 into space 6 and from there into capsule emptying chamber 12 through bores 72 and air inlets 18. This movement of air causes the capsule to rotate about its longitudinal axis and undergo reciprocating movement along that axis, causing the powdered medicament to empty into chamber 12 through the openings made by the two ends of pin 60. The medicament is then entrained by the airstream and passes through air outlet 24 and into the patient. During inhalation, air is also drawn from space 6 into passageways 32 and through openings 50 to channels 46, from where it passes into air outlet 24 as described above.
  • body portion 54 is drawn radially outward to the loading position shown in Figures 2 and 3. During this movement, the emptied capsule leaves the device by falling through opening 74 in base portion 2, which is coaxial with capsule emptying chamber 12. On reaching the loading position, the next capsule falls into capsule receiving chamber 22, and the operation described above is repeated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Un dispositif d'inhalation de médicament, à être utilisé avec des capsules de médicament, comprend une chambre destinée à vider la capsule (12) comportant une arrivée d'air (18) et une sortie d'air (24), et un tiroir (52) pour l'introduction de capsules (C) dans la chambre, le tiroir (52) étant pourvu de moyens de perçage (60) de capsule et pouvant être déplacé entre une position de chargement dans laquelle une capsule (C) peut y être placée et une position d'inhalation dans laquelle la capsule (C) est amenée à la chambre (12) où elle doit être vidée. Le tiroir (52) comprend une partie en corps (54) sur laquelle sont montés les moyens de perçage (60) et une partie d'appui (56) montée coulissante sur la partie en corps et qui s'appuie contre la capsule (C) au cours du mouvement du tiroir (52) de la position de chargement à celle d'inhalation, l'agencement étant tel que le mouvement relatif de la partie en corps (54) et de la partie d'appui dans la position d'inhalation du tiroir a pour résultat que le tiroir (52) adopte une configuration de perçage dans laquelle la capsule (C) est percée par les moyens de perçage (60) de la capsule.
PCT/GB1991/001357 1990-08-11 1991-08-09 Dispositif d'inhalation WO1992003175A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909017654A GB9017654D0 (en) 1990-08-11 1990-08-11 Improved device
GB9017654.6 1990-08-11
GB909024149A GB9024149D0 (en) 1990-11-07 1990-11-07 Inhalation device
GB9024149.8 1990-11-07

Publications (1)

Publication Number Publication Date
WO1992003175A1 true WO1992003175A1 (fr) 1992-03-05

Family

ID=26297496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/001357 WO1992003175A1 (fr) 1990-08-11 1991-08-09 Dispositif d'inhalation

Country Status (1)

Country Link
WO (1) WO1992003175A1 (fr)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5301666A (en) * 1991-12-14 1994-04-12 Asta Medica Aktiengesellschaft Powder inhaler
WO1994014491A1 (fr) * 1992-12-24 1994-07-07 Rhone-Poulenc Rorer Limited Inhalateurs
EP0711572A4 (fr) * 1994-05-26 1997-03-26 Unisia Jecs Corp Dispositif d'inhalation de medicaments et sa methode d'utilisation
EP0869079A2 (fr) 1997-04-04 1998-10-07 Plurichemie Anstalt Appareil pour orienter et positionner un objet allongé à dispenser
US5896855A (en) * 1992-12-24 1999-04-27 Rhone-Poulenc Rorer Limited Multi dose inhaler apparatus
EP0911047A1 (fr) * 1993-06-03 1999-04-28 Boehringer Ingelheim Pharma KG Porte-capsules
US6119688A (en) * 1991-08-26 2000-09-19 3M Innovative Properties Company Powder dispenser
WO2001017595A1 (fr) * 1999-09-04 2001-03-15 Innovata Biomed Limited Dispositif d'administration
WO2003000325A1 (fr) 2001-06-22 2003-01-03 Sofotec Gmbh & Co. Kg Systeme de desintegration de formulation de poudre et procede pour inhalateurs de poudre seche
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
US7025058B2 (en) 2001-04-26 2006-04-11 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
US7234464B2 (en) * 1999-12-18 2007-06-26 Meda Pharma Gmbh & Co. Kg. Storage system for powdered pharmaceuticals, and inhaler equipped with this system
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
EP1844805A1 (fr) * 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhalateur
EP1891974A1 (fr) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinaisons comportant des agents antimuscarinique et inhibiteurs PDE4
EP1891973A1 (fr) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinaisons comportant des agents antimuscarinique et inhibiteurs PDE4
WO2008107125A1 (fr) 2007-03-02 2008-09-12 Almirall, S.A. Nouveaux dérivés du 3-([1,2, 4] triazolo [4,3-a] pyridin-7-yl) benzamide
US7464704B2 (en) 2001-11-23 2008-12-16 Innovata Biomed Limited Medicament delivery assembly
EP2096105A1 (fr) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2108641A1 (fr) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
EP2196465A1 (fr) 2008-12-15 2010-06-16 Almirall, S.A. Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
WO2010072354A1 (fr) 2008-12-22 2010-07-01 Almirall, S.A. Sel de mésylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino }-1-hydroxyéthyl)-8-hydroxyquinoléin-2(1h)-one comme agoniste du récepteur β2 adrénergique
EP2221055A1 (fr) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one pour le traitement de la fonction pulmonaire
EP2221297A1 (fr) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one et son utiisation dans le traitement de maladies des voies respiratoires
WO2010097172A1 (fr) 2009-02-27 2010-09-02 Almirall, S.A. Nouveaux dérivés tétrahydropyrazolo[3,4-c]isoquinolin-5-amine
EP2263998A1 (fr) 2005-05-20 2010-12-22 Almirall S.A. Dérivés de 4-(2-amino-1-hydroxyéthyl)phénol agonistes du récepteur adrénergique beta-2
EP2322176A1 (fr) 2009-11-11 2011-05-18 Almirall, S.A. Nouveaux dérivés de 7-phényl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
US7954492B2 (en) 2002-01-24 2011-06-07 Almirall, S.A. Pharmaceutical powder cartridge, and inhaler equipped with same
EP2380890A1 (fr) 2010-04-23 2011-10-26 Almirall, S.A. Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2394998A1 (fr) 2010-05-31 2011-12-14 Almirall, S.A. Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
WO2012041476A1 (fr) 2010-09-30 2012-04-05 Almirall, S.A. Dérivés de pyridine et d'isoquinoléine en tant qu'inhibiteurs des syk- et jak-kinases
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
WO2012069202A1 (fr) 2010-11-26 2012-05-31 Almirall,S.A. Dérivés d'imidazo[1,2-b]pyridazine et d'imidazo[4,5-b]pyridine en tant qu'inhibiteurs des jak
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
EP2518070A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
EP2518071A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
EP2526945A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Nouveaux antagonistes de CRTH2
EP2527344A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
EP2548876A1 (fr) 2011-07-18 2013-01-23 Almirall, S.A. Nouveaux antagonistes de CRTH2
EP2548863A1 (fr) 2011-07-18 2013-01-23 Almirall, S.A. Nouveaux antagonistes de CRTH2
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
CN103052417A (zh) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 干粉末吸入器
CN103052418A (zh) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 干粉末吸入器
EP2592077A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
EP2647627A1 (fr) 2012-04-02 2013-10-09 Almirall, S.A. Sels de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phényléthoxy)phényl]éthyl}amino)- 1-hydroxyéthyl]-8- hydroxyquinolin-2(1h)-one
EP2666465A1 (fr) 2012-05-25 2013-11-27 Almirall, S.A. Nouveau dosage et formule
EP2668941A1 (fr) 2012-05-31 2013-12-04 Almirall, S.A. Nouveau dosage et formulation d'abediterol
EP2462973A3 (fr) * 2004-09-15 2013-12-11 Optinose AS Dispositif d'administration nasale
EP2707067A1 (fr) * 2011-05-12 2014-03-19 Alfred Von Schuckmann Dispositif servant à inhaler des substances pulvérulentes
WO2014060431A1 (fr) 2012-10-16 2014-04-24 Almirall, S.A. Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k
EP2738172A1 (fr) 2012-11-28 2014-06-04 Almirall, S.A. Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
WO2014095920A1 (fr) 2012-12-18 2014-06-26 Almirall, S.A. Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
WO2014124757A1 (fr) 2013-02-15 2014-08-21 Almirall, S.A. Dérivés de pyrrolotriazinone utilisés en tant qu'inhibiteurs de pi3k
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
EP2848615A1 (fr) 2013-07-03 2015-03-18 Almirall, S.A. Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
WO2015091285A1 (fr) 2013-12-19 2015-06-25 Almirall S.A. Formulation de dosage comprenant du salmétérol et du propionate de fluticasone
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
WO2016170009A1 (fr) 2015-04-21 2016-10-27 Almirall, S.A. Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
WO2016202800A1 (fr) 2015-06-16 2016-12-22 Almirall, S.A. Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2019030298A1 (fr) 2017-08-08 2019-02-14 Almirall, S.A. Nouveaux composés activant la voie nrf2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1551053A (fr) * 1966-09-17 1968-12-27
DE2704574A1 (de) * 1976-02-10 1977-08-11 Allen & Hanburys Ltd Inhalationsvorrichtung
EP0147755A2 (fr) * 1983-12-17 1985-07-10 Boehringer Ingelheim Kg Inhalateur
EP0406893A1 (fr) * 1989-07-07 1991-01-09 SOMOVA S.p.A. Dispositif pour inhaler un médicament

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1551053A (fr) * 1966-09-17 1968-12-27
DE2704574A1 (de) * 1976-02-10 1977-08-11 Allen & Hanburys Ltd Inhalationsvorrichtung
EP0147755A2 (fr) * 1983-12-17 1985-07-10 Boehringer Ingelheim Kg Inhalateur
EP0406893A1 (fr) * 1989-07-07 1991-01-09 SOMOVA S.p.A. Dispositif pour inhaler un médicament

Cited By (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119688A (en) * 1991-08-26 2000-09-19 3M Innovative Properties Company Powder dispenser
US5301666A (en) * 1991-12-14 1994-04-12 Asta Medica Aktiengesellschaft Powder inhaler
US5896855A (en) * 1992-12-24 1999-04-27 Rhone-Poulenc Rorer Limited Multi dose inhaler apparatus
WO1994014491A1 (fr) * 1992-12-24 1994-07-07 Rhone-Poulenc Rorer Limited Inhalateurs
EP0806214A3 (fr) * 1992-12-24 1998-06-24 Rhone-Poulenc Rorer Limited Inhalateur
EP0911047A1 (fr) * 1993-06-03 1999-04-28 Boehringer Ingelheim Pharma KG Porte-capsules
US5715811A (en) * 1994-05-26 1998-02-10 Unisia Jecs Corporation Inhaling type medicine administering device and using method therefor
EP0711572A4 (fr) * 1994-05-26 1997-03-26 Unisia Jecs Corp Dispositif d'inhalation de medicaments et sa methode d'utilisation
US5881721A (en) * 1997-04-04 1999-03-16 Plurichemie Anstalt Apparatus for orienting and positioning an elongate object for dispensing
EP0869079A2 (fr) 1997-04-04 1998-10-07 Plurichemie Anstalt Appareil pour orienter et positionner un objet allongé à dispenser
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
USRE46417E1 (en) 1999-07-14 2017-05-30 Almirall, S.A. Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US7571724B2 (en) 1999-09-04 2009-08-11 Innovata Biomed Limited Delivery device
AU779396B2 (en) * 1999-09-04 2005-01-20 Innovata Biomed Limited Delivery device
WO2001017595A1 (fr) * 1999-09-04 2001-03-15 Innovata Biomed Limited Dispositif d'administration
US7571723B2 (en) 1999-09-04 2009-08-11 Innovata Biomed Limited Delivery device
US7219665B1 (en) 1999-09-04 2007-05-22 Innovata Biomed Limited Delivery device
US8820321B2 (en) 1999-12-18 2014-09-02 Almirall, S.A. Storage system for powdered pharmaceuticals, and inhaler equipped with this system
US8375940B2 (en) 1999-12-18 2013-02-19 Almirall, S.A. Storage system for powdered pharmaceuticals and inhaler equipped with this system
US7234464B2 (en) * 1999-12-18 2007-06-26 Meda Pharma Gmbh & Co. Kg. Storage system for powdered pharmaceuticals, and inhaler equipped with this system
US7025058B2 (en) 2001-04-26 2006-04-11 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
WO2003000325A1 (fr) 2001-06-22 2003-01-03 Sofotec Gmbh & Co. Kg Systeme de desintegration de formulation de poudre et procede pour inhalateurs de poudre seche
US7464704B2 (en) 2001-11-23 2008-12-16 Innovata Biomed Limited Medicament delivery assembly
US7954492B2 (en) 2002-01-24 2011-06-07 Almirall, S.A. Pharmaceutical powder cartridge, and inhaler equipped with same
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
EP2774623A1 (fr) 2004-05-31 2014-09-10 Almirall S.A. Combinaisons comportant des agents anti-muscariniques et agonistes bêta-adrénergiques
EP2292267A2 (fr) 2004-05-31 2011-03-09 Almirall S.A. Combinaisons comportant des agents anti-muscariniques et agonistes béta-adrénergiques
EP2002843A2 (fr) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinaisons comportant des agents anti-muscariniques et agonistes béta-adrénergiques
EP2002845A2 (fr) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinaisons comprenant des agents anti-muscariniques et des corticostéroïdes
EP2002844A2 (fr) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinaisons comportant des agents anti-muscariniques et agonistes béta-adrénergiques
EP2138188A1 (fr) 2004-05-31 2009-12-30 Almirall, S.A. Combinaisons comportant des agents anti-muscariniques et agonistes bêta-adrénergiques
EP1905451A1 (fr) 2004-05-31 2008-04-02 Laboratorios Almirall, S.A. Combinaisons comprenant des agents anti-muscariniques et des corticostéroïdes
EP1891973A1 (fr) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinaisons comportant des agents antimuscarinique et inhibiteurs PDE4
EP1891974A1 (fr) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinaisons comportant des agents antimuscarinique et inhibiteurs PDE4
EP2774622A1 (fr) 2004-05-31 2014-09-10 Almirall, S.A. Combinaisons comportant des agents anti-muscariniques et agonistes bêta-adrénergiques
EP2319538A2 (fr) 2004-05-31 2011-05-11 Almirall S.A. Combinaisons comportant des agents anti-muscariniques et agonistes béta-adrénergiques
US10398859B2 (en) 2004-09-15 2019-09-03 Optinose As Nasal delivery devices
EP2462973A3 (fr) * 2004-09-15 2013-12-11 Optinose AS Dispositif d'administration nasale
US7964615B2 (en) 2005-05-20 2011-06-21 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
US8242177B2 (en) 2005-05-20 2012-08-14 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
EP2263998A1 (fr) 2005-05-20 2010-12-22 Almirall S.A. Dérivés de 4-(2-amino-1-hydroxyéthyl)phénol agonistes du récepteur adrénergique beta-2
US8420669B2 (en) 2005-05-20 2013-04-16 Laboratories Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor
US8584669B2 (en) 2006-04-13 2013-11-19 Boehringer Ingelheim International Gmbh Inhaler
JP2015120074A (ja) * 2006-04-13 2015-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
WO2007118648A1 (fr) * 2006-04-13 2007-10-25 Boehringer Ingelheim International Gmbh Inhalateur
JP2009533111A (ja) * 2006-04-13 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
EP1844805A1 (fr) * 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhalateur
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
WO2008107125A1 (fr) 2007-03-02 2008-09-12 Almirall, S.A. Nouveaux dérivés du 3-([1,2, 4] triazolo [4,3-a] pyridin-7-yl) benzamide
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2096105A1 (fr) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2946769A1 (fr) 2008-03-13 2015-11-25 Almirall, S.A. Composition à inhaler comprenant de l'aclidinium pour le traitement de l'asthme
EP2946768A1 (fr) 2008-03-13 2015-11-25 Almirall, S.A. Composition à inhaler comprenant de l'aclidinium pour le traitement de l'asthme
EP2954890A1 (fr) 2008-03-13 2015-12-16 Almirall, S.A. Composition à inhaler comprenant de l'aclidinium pour le traitement de l'asthme
EP2954891A1 (fr) 2008-03-13 2015-12-16 Almirall, S.A. Composition à inhaler comprenant de l'aclidinium pour le traitement de l'asthme
EP2954889A1 (fr) 2008-03-13 2015-12-16 Almirall, S.A. Composition à inhaler comprenant de l'aclidinium pour le traitement de l'asthme et des maladies respiratoires obstructives chroniques
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
EP2108641A1 (fr) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
EP2196465A1 (fr) 2008-12-15 2010-06-16 Almirall, S.A. Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
WO2010072354A1 (fr) 2008-12-22 2010-07-01 Almirall, S.A. Sel de mésylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino }-1-hydroxyéthyl)-8-hydroxyquinoléin-2(1h)-one comme agoniste du récepteur β2 adrénergique
US8563731B2 (en) 2008-12-22 2013-10-22 Almirall, S.A. Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
WO2010094484A1 (fr) 2009-02-18 2010-08-26 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one et son utilisation dans le traitement des maladies pulmonaires
EP2221297A1 (fr) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one et son utiisation dans le traitement de maladies des voies respiratoires
EP2221055A1 (fr) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one pour le traitement de la fonction pulmonaire
WO2010094483A1 (fr) 2009-02-18 2010-08-26 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(ih)-one utilisé dans le traitement de normalisation de la fonction pulmonaire
EP2226323A1 (fr) 2009-02-27 2010-09-08 Almirall, S.A. Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine
WO2010097172A1 (fr) 2009-02-27 2010-09-02 Almirall, S.A. Nouveaux dérivés tétrahydropyrazolo[3,4-c]isoquinolin-5-amine
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2322176A1 (fr) 2009-11-11 2011-05-18 Almirall, S.A. Nouveaux dérivés de 7-phényl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
WO2011057757A1 (fr) 2009-11-11 2011-05-19 Almirall, S.A. Nouveaux dérivés de 7-phényl-[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one
EP2380890A1 (fr) 2010-04-23 2011-10-26 Almirall, S.A. Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
WO2011141180A1 (fr) 2010-05-13 2011-11-17 Almirall, S.A. Nouveaux dérivés de cyclohexylamine ayant des activités d'agoniste des récepteurs β2-adrénergiques et d'antagoniste des récepteurs muscariniques m3
EP2394998A1 (fr) 2010-05-31 2011-12-14 Almirall, S.A. Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
CN103052418A (zh) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 干粉末吸入器
CN103052418B (zh) * 2010-07-07 2015-04-01 阿普塔尔法国简易股份公司 干粉末吸入器
CN103052417A (zh) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 干粉末吸入器
EP2441755A1 (fr) 2010-09-30 2012-04-18 Almirall, S.A. Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
WO2012041476A1 (fr) 2010-09-30 2012-04-05 Almirall, S.A. Dérivés de pyridine et d'isoquinoléine en tant qu'inhibiteurs des syk- et jak-kinases
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
WO2012069175A1 (fr) 2010-11-25 2012-05-31 Almirall, S.A. Nouveaux dérivés de pyrazole possédant un comportement antagoniste de crth2
WO2012069202A1 (fr) 2010-11-26 2012-05-31 Almirall,S.A. Dérivés d'imidazo[1,2-b]pyridazine et d'imidazo[4,5-b]pyridine en tant qu'inhibiteurs des jak
EP2463289A1 (fr) 2010-11-26 2012-06-13 Almirall, S.A. Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2518070A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
EP2518071A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
WO2012146667A1 (fr) 2011-04-29 2012-11-01 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs de pi3k
EP2707067A1 (fr) * 2011-05-12 2014-03-19 Alfred Von Schuckmann Dispositif servant à inhaler des substances pulvérulentes
WO2012160030A1 (fr) 2011-05-25 2012-11-29 Almirall, S.A. Dérivés de pyridin-2(1h)-one utiles en tant que médicaments pour le traitement de troubles myéloprolifératifs, du rejet de greffe, de maladies à médiation immunitaire et inflammatoires
EP2526945A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Nouveaux antagonistes de CRTH2
EP2527344A1 (fr) 2011-05-25 2012-11-28 Almirall, S.A. Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires
WO2013010880A1 (fr) 2011-07-18 2013-01-24 Almirall, S.A. Nouveaux antagonistes de crth2
EP2548863A1 (fr) 2011-07-18 2013-01-23 Almirall, S.A. Nouveaux antagonistes de CRTH2
WO2013010881A1 (fr) 2011-07-18 2013-01-24 Almirall, S.A. Nouveaux antagonistes de crth2
EP2548876A1 (fr) 2011-07-18 2013-01-23 Almirall, S.A. Nouveaux antagonistes de CRTH2
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
WO2013017461A1 (fr) 2011-08-01 2013-02-07 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de jak
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
WO2013068552A1 (fr) 2011-11-11 2013-05-16 Almirall, S.A. Nouveaux dérivés de cyclohexilamine ayant des activités d'agoniste des récepteurs β2-adrénergique et d'antagoniste des récepteurs muscariniques m3
WO2013068554A1 (fr) 2011-11-11 2013-05-16 Almirall, S.A. Nouveaux dérivés de cyclohexilamine ayant des activités d'agoniste des récepteurs β2-adrénergique et d'antagoniste des récepteurs muscariniques m3
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2592077A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
WO2013139712A1 (fr) 2012-03-20 2013-09-26 Almirall, S.A. Nouvelles formes cristallines polymorphes d'héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-(r)-hydroxyéthyl)-8-hydroxyquinoléin-2(1h)-one utilisées comme agoniste du récepteur adrénergique β2
US9346759B2 (en) 2012-03-20 2016-05-24 Almirall, S.A. Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
WO2013149959A1 (fr) 2012-04-02 2013-10-10 Almirall, S.A. Sels de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phényléthoxy)phényl]éthyl}amino)-1-hydroxyéthyl]-8-hydroxyquinoléin-2(1h)-one
EP2647627A1 (fr) 2012-04-02 2013-10-09 Almirall, S.A. Sels de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phényléthoxy)phényl]éthyl}amino)- 1-hydroxyéthyl]-8- hydroxyquinolin-2(1h)-one
WO2013175013A1 (fr) 2012-05-25 2013-11-28 Almirall, S.A. Nouveau dosage et nouvelle formulation
EP2666465A1 (fr) 2012-05-25 2013-11-27 Almirall, S.A. Nouveau dosage et formule
EP2668941A1 (fr) 2012-05-31 2013-12-04 Almirall, S.A. Nouveau dosage et formulation d'abediterol
WO2013178742A1 (fr) 2012-05-31 2013-12-05 Almirall, S.A. Nouvelle forme de dosage et nouvelle formulation d'abéditérol
WO2014060431A1 (fr) 2012-10-16 2014-04-24 Almirall, S.A. Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k
EP2738172A1 (fr) 2012-11-28 2014-06-04 Almirall, S.A. Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
WO2014095920A1 (fr) 2012-12-18 2014-06-26 Almirall, S.A. Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
WO2014124757A1 (fr) 2013-02-15 2014-08-21 Almirall, S.A. Dérivés de pyrrolotriazinone utilisés en tant qu'inhibiteurs de pi3k
EP2848615A1 (fr) 2013-07-03 2015-03-18 Almirall, S.A. Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
WO2015091287A1 (fr) 2013-12-19 2015-06-25 Almirall S.A. Formulation pharmaceutique comprenant du salmétérol et du propionate de fluticasone
WO2015091285A1 (fr) 2013-12-19 2015-06-25 Almirall S.A. Formulation de dosage comprenant du salmétérol et du propionate de fluticasone
WO2016170009A1 (fr) 2015-04-21 2016-10-27 Almirall, S.A. Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
WO2016202800A1 (fr) 2015-06-16 2016-12-22 Almirall, S.A. Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k
WO2019030298A1 (fr) 2017-08-08 2019-02-14 Almirall, S.A. Nouveaux composés activant la voie nrf2

Similar Documents

Publication Publication Date Title
WO1992003175A1 (fr) Dispositif d'inhalation
US5320714A (en) Powder inhalator
EP0028162B1 (fr) Dispositifs d'inhalation pour l'administration de médicaments poudreux actionnés par la respiration
US5337740A (en) Inhalation devices
EP0632734B1 (fr) Distributeur a jet de poudre pour traitements par inhalation de medicament
US5388572A (en) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5429122A (en) Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
EP0640354B1 (fr) Inhalateur pour poudres à tourbillon
US7461653B2 (en) Single dose inhaler
JP4195005B2 (ja) 粉末吸入装置
CA2028192C (fr) Inhalateur multidose pour medicaments en poudre
KR100321814B1 (ko) 건분말흡입기
EP0079478A1 (fr) Dispositif inhalateur de médicaments
CA2092614A1 (fr) Un inhalateur
DE69230179T2 (de) Pulverspender
EP0559663A1 (fr) Dispositif d'inhalation.
HU225186B1 (hu) Porinhaláló eszköz és eljárás
BG99579A (bg) Инхалатор за сухо прахообразно вещество
EP0488609A1 (fr) Inhalateur de poudre
CN103096958A (zh) 干粉末吸入器使用方法
JP4723785B2 (ja) 粉末吸入装置
GB2061735A (en) Breath actuated device for administration of powdered medicaments by inhalation
AU659110C (en) Inhalation device
SI9210252A (sl) Inhalator
CA2076938A1 (fr) Inhalateur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA